Various preclinical reports and a recent clinical study suggest that the FGF19-FGFR4 signaling network is an oncogenic driver of certain forms of HCC and other solid malignancies with aberrant FGF19 expression [14, 15, 19]. The gene discussed is FGF19; the disease is hepatocellular carcinoma.